Lower Risks of Dementia, Stroke, and Mortality Associated with GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity
Recent research highlights that GLP-1 receptor agonists significantly decrease the risk of dementia, stroke, and death in individuals with type 2 diabetes and obesity, offering promising neuroprotective benefits beyond glucose management.
A recent study published in July 2025 in JAMA Network Open reveals that adults with type 2 diabetes and obesity who are treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) experience a significant reduction in the risks of developing dementia, ischemic stroke, and overall mortality compared to those on other diabetic medications. The research analyzed electronic health records of over 60,000 individuals, ensuring a balanced comparison between those using GLP-1 RAs such as semaglutide and tirzepatide and those on other antidiabetic drugs like metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones, and alpha-glucosidase inhibitors.
Participants were followed over seven years, and the findings showed that users of GLP-1 RAs had hazard ratios indicating a lowered risk for dementia (0.63), ischemic stroke (0.81), and death from any cause (0.70). Notably, the protective effects were more pronounced among individuals aged 60 and above, women, and those with a body mass index ranging from 30 to 40. However, the study did not observe significant differences in the risks for Parkinson's disease or intracerebral hemorrhage.
The authors suggest that these outcomes point toward a potential role of GLP-1 RAs in reducing neurodegenerative and cerebrovascular risks in high-risk populations, emphasizing the importance of these medications not just for glycemic control but also for their broader neurological and cardiovascular benefits.
Source: https://medicalxpress.com/news/2025-07-dementia-ischemic-mortality-glp-receptor.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Breakthrough in Chagas Disease: Antibodies Show Promising Potential for Vaccine Development
Innovative research uncovers highly effective neutralizing antibodies against Trypanosoma cruzi, paving the way for vaccine development to combat Chagas disease—one of the world's most neglected tropical illnesses.
Research Highlights the Impact of Doctors' Trust in Patients on Antibiotic Prescriptions
A Swiss study reveals that greater trust from doctors towards patients can reduce unnecessary requests for antibiotics, helping combat resistance and improve prescribing practices.
FDA Approves Updated COVID-19 Vaccines with Access Restrictions for Certain Age Groups
The FDA has approved updated COVID-19 vaccines from Pfizer, Moderna, and Novavax, but with new restrictions limiting access for some children and adults, especially those under 6 years old. The changes aim to target newer variants while emphasizing high-risk populations.
Why the ALS Drug BIIB078 Failed Despite Target Engagement
A groundbreaking study explains why the promising ALS drug BIIB078 failed despite reaching its target in the CNS. The research highlights the challenges in drug delivery and the need for better biomarkers to measure treatment effectiveness in ALS. Source: Emory University.